Butidrine (INNTooltip International Nonproprietary Name), sold under the brand names Betabloc, Butidrate, and Recetan among others, is a beta blocker (or β-adrenergic receptor antagonist) related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3][4] It is not cardioselective (i.e., is not selective for the β1-adrenergic receptor over the β2-adrenergic receptor).[5] It has membrane stabilizing activity but no intrinsic sympathomimetic activity (i.e., partial agonist activity).[6] Similarly to certain other beta blockers, butidrine additionally possesses local anesthetic properties.[7]

References

  1. ^ Bristol JA (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. p. 111. ISBN 978-0-471-09228-5.
  2. ^ Drug Metabolism Reviews. Marcel Dekker. 1972.
  3. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 58–. ISBN 978-94-011-4439-1.
  4. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 197–. ISBN 978-1-4757-2085-3.
  5. ^ Sokabe, Hirofumi (1985). "A new classification of β-adrenoceptor blocking drugs". Trends in Pharmacological Sciences. 6: 107–109. doi:10.1016/0165-6147(85)90051-3.
  6. ^ Fitzgerald JD (1969). "Perspectives in adrenergic beta-receptor blockade". Clin Pharmacol Ther. 10 (3): 292–306. doi:10.1002/cpt1969103292. PMID 4894830.
  7. ^ Charlier R (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.


Allikas: https://en.wikipedia.org/wiki/Butidrine
No tags for this post.